CLENT LIFE SCIENCE LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2020

Folkes Worton LLP 15-17 Church Street Stourbridge West Midlands DY8 1LU

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2020

	Page
Company Information	1
Chartered Accountants' Report	2
Statement of Financial Position	3
Notes to the Financial Statements	5

CLENT LIFE SCIENCE LIMITED

COMPANY INFORMATION FOR THE YEAR ENDED 31 JANUARY 2020

DIRECTOR: Mr. D. Harris

REGISTERED OFFICE: 15-17 Church Street

Stourbridge West Midlands DY8 1LU

BUSINESS ADDRESS: Suite 3, Faraday House

King William Street

Amblecote Stourbridge West Midlands DY8 4HD

REGISTERED NUMBER: 06790466 (England and Wales)

ACCOUNTANTS: Folkes Worton LLP

15-17 Church Street

Stourbridge West Midlands DY8 1LU

BANKERS: Barclays Bank Plc

81 High Street Stourbridge West Midlands DY8 1EB

CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE UNAUDITED FINANCIAL STATEMENTS OF CLENT LIFE SCIENCE LIMITED

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Statement of Financial Position. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Clent Life Science Limited for the year ended 31 January 2020 which comprise the Income Statement, Statement of Financial Position, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Clent Life Science Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Clent Life Science Limited and state those matters that we have agreed to state to the director of Clent Life Science Limited in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Clent Life Science Limited and its director for our work or for this report.

It is your duty to ensure that Clent Life Science Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Clent Life Science Limited. You consider that Clent Life Science Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Clent Life Science Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Folkes Worton LLP 15-17 Church Street Stourbridge West Midlands DY8 ILU

17 June 2020

STATEMENT OF FINANCIAL POSITION 31 JANUARY 2020

		2020		2019	
	Notes	£	£	£	£
FIXED ASSETS					
Tangible assets	4		4,232		4,610
Investments	5		<u>70</u>		70
			4,302		4,680
CURRENT ASSETS					
Stocks		69,827		124,447	
Debtors	6	291,855		126,454	
Cash at bank and in hand		102,123_		41,589	
		463,805		292,490	
CREDITORS					
Amounts falling due within one year	7	353,278_		<u>169,765</u>	
NET CURRENT ASSETS			110,527_		122,725
TOTAL ASSETS LESS CURRENT					
LIABILITIES			114,829		127,405
PROVISIONS FOR LIABILITIES			804_		<u>876</u>
NET ASSETS			114,025		126,529
CAPITAL AND RESERVES					
Called up share capital			1		1
Retained earnings			114,024		126,528
SHAREHOLDERS' FUNDS			114,025		126,529

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2020 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial

statements, so far as applicable to the company.

Page 3 continued...

STATEMENT OF FINANCIAL POSITION - continued 31 JANUARY 2020

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 17 June 2020 and were signed by:

Mr. D. Harris - Director

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2020

1. STATUTORY INFORMATION

Clent Life Science Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover represents net sales of goods/services, excluding value added tax

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 15% on reducing balance Computer equipment - 33% on reducing balance

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2019 - 2).

Page 5 continued...

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 JANUARY 2020

4.	TANGIBLE FIXED ASSETS				
		Plant and machinery £	Fixtures and fittings £	Computer equipment	Totals £
	COST				
	At 1 February 2019	5	5,100	1,874	6,979
	Additions		<u>-</u> _	<u> 550</u>	550
	At 31 January 2020	5	5,100	2,424	<u>7,529</u>
	DEPRECIATION				
	At 1 February 2019	5	789	1,575	2,369
	Charge for year		<u>647</u>	<u> 281</u>	928
	At 31 January 2020	5	1,436	<u> 1,856</u>	3,297
	NET BOOK VALUE				
	At 31 January 2020		<u>3,664</u>	<u> 568</u>	<u>4,232</u>
	At 31 January 2019		4,311	<u>299</u>	<u>4,610</u>
5.	FIXED ASSET INVESTMENTS COST				Shares in group undertakings
	At 1 February 2019				
	and 31 January 2020				70
	NET BOOK VALUE				
	At 31 January 2020				70
	At 31 January 2019				70
6.	DEBTORS: AMOUNTS FALLING DUE WIT	THIN ONE YEAR			
•				2020	2019
				£	£
	Trade debtors			41,296	70,695
	Amounts owed by group undertakings			10,379	-
	Other debtors			240,180	<u>55,759</u>
				291,855	126,454

Page 6 continued...

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 JANUARY 2020

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Trade creditors	303,639	139,124
Amounts owed to group undertakings	-	24,477
Taxation and social security	29,533	4,652
Other creditors	20,106	1,512
	353,278	169,765

8. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 January 2020 and 31 January 2019:

	2020	2019
	£	£
Mr. D. Harris		
Balance outstanding at start of year	26,258	28,289
Amounts advanced	40,021	25,841
Amounts repaid	(66,099)	(27,872)
Amounts written off	-	-
Amounts waived	-	-
Balance outstanding at end of year	<u> 180</u>	26,258

9. RELATED PARTY DISCLOSURES

Clent Life Science Limited owns 70% of the issued share capital in Analox Instruments Limited. At the balance sheet date Analox Instruments Limited owed Clent Life Science Limited £10,379 (2019: Clent Life Science Limited owed Analox Instruments Limited £24,477).

10. ULTIMATE CONTROLLING PARTY

The company is controlled by Mr. D. Harris by virtue of his 100% shareholding in the company.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.